DDInter740 DDInter1464
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimipramine
Trimipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) binds {v} (Gene) SCN4A
SCN4A {u} (Gene) is bound by {v} (Compound) Propofol
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Entrectinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Digitoxin
Digitoxin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Tizanidine
Tizanidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Picosulfuric acid
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Picosulfuric acid
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) binds SCN4A (Gene) and SCN4A (Gene) is bound by Propofol (Compound) and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Tizanidine (Compound) and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid